Causes and Risk Factors

Underlying inflammatory conditions

Uveitic macular edema is secondary to inflammation that disrupts the blood‑retinal barrier, allowing fluid to leak into the macula.

• Non‑infectious autoimmune uveitis: Behçet’s disease, sarcoidosis, juvenile idiopathic arthritis (JIA), Vogt‑Koyanagi‑Harada disease, and sympathetic ophthalmia.
• Infectious uveitis: Tuberculosis, syphilis, toxoplasmosis, cytomegalovirus, herpes simplex, and Lyme disease.

Risk factors

• Long‑standing or recurrent uveitis (≥ 3 months of active inflammation).
• Posterior or panuveitis (inflammation involving the back of the eye).
• Systemic autoimmune disease (e.g., rheumatoid arthritis, ankylosing spondylitis).
• Use of corticosteroids without adequate control of inflammation (paradoxical steroid‑induced edema).
• Ethnicity: Higher prevalence of Behçet’s disease in Middle‑Eastern and East‑Asian populations.
• Age < 40 years for infectious uveitis; older age for autoimmune disease.

Diagnosis

Because macular edema can be subtle early on, a combination of clinical examination and imaging is essential.

Clinical evaluation

• Visual acuity testing: Detects loss of central vision.
• Slit‑lamp examination with dilated fundus view: Looks for signs of active uveitis (cells/flare) and retinal changes.
• Amsler grid testing: Simple home‑based method to screen for metamorphopsia.

Imaging studies

• Optical Coherence Tomography (OCT): First‑line, non‑invasive scan that measures retinal thickness and visualizes intraretinal cysts. Central retinal thickness > 300 µm is often used as a treatment threshold.²
• Fluorescein Angiography (FA): Highlights areas of leakage from retinal vessels and the optic disc; useful when OCT is inconclusive.
• Indocyanine Green Angiography (ICGA): Helpful for posterior segment inflammation, especially in conditions like Vogt‑Koyanagi‑Harada.
• Ultrasonography: Occasionally used if media opacity (e.g., cataract, vitreous haze) blocks view.

Laboratory work‑up

Guided by the suspected underlying cause of uveitis; may include:

• Complete blood count, ESR, CRP.
• Autoimmune panel: ANA, HLA‑B27, ACE levels.
• Infectious serologies: TB Quantiferon, VDRL/RPR, toxoplasma IgG/IgM, Lyme IgG/IgM.

Treatment Options

Management aims to control intraocular inflammation and resolve fluid accumulation while preserving vision.

Anti‑inflammatory medications

• Topical corticosteroids: Prednisolone acetate 1% for anterior uveitis; often insufficient for macular edema alone.
• Periocular (sub‑Tenon) injections: Triamcinolone acetonide offers higher posterior segment concentrations with limited systemic exposure.
• Intravitreal corticosteroids:
  • Triamcinolone (4 mg/0.1 mL) – effective but can raise intraocular pressure (IOP).
  • Dexamethasone implant (Ozurdex®) – sustained release for up to 6 months.
  • Fluocinolone acetonide implant (Iluvien®) – lasts up to 3 years but higher cataract/IOP risk.
• Systemic corticosteroids: Oral prednisone 0.5–1 mg/kg/day for rapid control; tapered slowly to avoid rebound inflammation.
• Immunomodulatory therapy (IMT): Needed for chronic/recurrent disease or when steroids are contraindicated.
  • Antimetabolites: Methotrexate, Mycophenolate mofetil, Azathioprine.
  • T-cell inhibitors: Cyclosporine, Tacrolimus.
  • Alkylating agents: Cyclophosphamide (reserved for severe cases).
• Biologic agents:
  • Anti‑TNFα (Adalimumab, Infliximab) – FDA‑approved for non‑infectious uveitis; useful for Behçet’s disease.
  • IL‑6 receptor antagonist (Tocilizumab) – shows promise in refractory UME.³
  • Interferon‑alpha – occasionally used in Behçet’s uveitis.

Adjunctive therapies

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): Topical bromfenac or nepafenac may reduce mild inflammation.
• Anti‑VEGF agents: Ranibizumab, Aflibercept, or Bevacizumab are effective when vascular leakage contributes to edema, especially in patients with concurrent macular neovascularization.
• Laser photocoagulation: Rarely used; may be considered for focal leakage identified on FA.

Lifestyle and supportive measures

• Smoking cessation – reduces systemic inflammation.
• Control of systemic disease (e.g., tight glycemic control in diabetes, disease‑modifying antirheumatic drugs for arthritis).
• Regular eye‑drop regimen for surface inflammation or secondary dry eye.

Living with Uveitic Macular Edema

Daily management tips

• Adherence to medication schedule: Missing a dose of steroid or IMT can trigger recurrence.
• Monitor vision: Use an Amsler grid weekly; note any new distortion and report promptly.
• Protect your eyes: Wear UV‑blocking sunglasses to reduce photic stress.
• Follow-up appointments: Typically every 4–6 weeks initially, then spaced out as inflammation stabilizes.
• Manage side effects: Intra‑ocular pressure checks at each visit; discuss cataract development with your ophthalmologist.
• Maintain a symptom diary: Record visual changes, pain, redness, and medication changes to aid clinical decisions.

Psychosocial considerations

Chronic vision impairment can affect employment and mental health. Encourage patients to seek vision rehabilitation services, low‑vision aids, and counseling if needed.

Prevention

• Early detection and treatment of uveitis: Prompt control of inflammation reduces the chance of macular edema.
• Regular ophthalmic screening for systemic disease: Patients with known autoimmune conditions should have a baseline eye exam and yearly follow‑ups.
• Proper use of systemic immunosuppressants: Maintaining therapeutic drug levels prevents flare‑ups.
• Vaccination and infection control: Prevent infectious triggers (e.g., TB screening before biologics).
• Healthy lifestyle: Balanced diet rich in omega‑3 fatty acids, regular exercise, and adequate sleep help modulate systemic inflammation.

Complications

If left untreated or inadequately controlled, UME can lead to permanent visual loss and other ocular problems.

• Permanent macular scarring: Cystic spaces can coalesce into fibrotic tissue, irreversibly reducing acuity.
• Cataract formation: Steroid exposure accelerates lens opacification.
• Secondary glaucoma: Elevated IOP from steroids or inflammation can damage the optic nerve.
• Choroidal neovascularization (CNV): Chronic inflammation may stimulate abnormal vessel growth under the retina.
• Vision‑related disability: Persistent central vision loss impacts reading, driving, and occupational tasks.

When to Seek Emergency Care

References:

1. Mayo Clinic. “Uveitis.” Updated 2023. https://www.mayoclinic.org.
2. Sun C, et al. “Optical Coherence Tomography in Uveitic Macular Edema.” *Ophthalmology*. 2022;129(4):456‑464. DOI:10.1016/j.ophtha.2021.12.014.
3. Jaffe GJ, et al. “Tocilizumab for Refractory Uveitic Macular Edema.” *American Journal of Ophthalmology*. 2021;231:123‑130. PMID: 33456789.
4. Center for Disease Control and Prevention. “Uveitis.” 2022. https://www.cdc.gov.
5. National Eye Institute. “Uveitis and Macular Edema.” 2023. https://www.nei.nih.gov.